Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Tumor Heterogeneity Confounds and Illuminates: Assessing the implications

Certain biological features are inherent traits of cancer, yet some of them still hold mysteries for researchers and clinicians. The heterogeneity of a tumor mass is an old concept that has lately become both a puzzling factor and a feature that should be harnessed to better understand tumor vulnerabilities. Improved scientific approaches to further determine and uncover the meaning of these heterogeneous features are still needed to translate findings into ways to develop therapies, identify drug response biomarkers and stratify patients. In Bedside to Bench, Maria Kleppe and Ross L. Levine look at recent clinical cancer trials that have advanced the field and discuss main questions regarding the role of tumor heterogeneity in predicting therapeutic response and tumor progression. In addition, they raise awareness of the relevance of the interactions among different tumor entities and their contribution to the malignancy of the whole tumor. In Bench to Bedside, Kornelia Polyak peruses studies that uncover specific mutations conferring endocrine drug resistance in breast tumors and that add to our knowledge of the evolution and architecture of tumors, and she discusses how this can be used to implement drug regimens.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Biological and clinical consequences of tumor heterogeneity.

Katie Vicari


  1. Vogelstein, B. et al. Science 339, 1546–1558 (2013).

    CAS  Article  Google Scholar 

  2. Ciriello, G. et al. Nat. Genet. 45, 1127–1133 (2013).

    CAS  Article  Google Scholar 

  3. Fearon, E.R. & Vogelstein, B. Cell 61, 759–767 (1990).

    CAS  Article  Google Scholar 

  4. Patel, J.P. et al. N. Engl. J. Med. 366, 1079–1089 (2012).

    CAS  Article  Google Scholar 

  5. Lawrence, M.S. et al. Nature 499, 214–218 (2013).

    CAS  Article  Google Scholar 

  6. Ding, L. et al. Nature 481, 506–510 (2012).

    CAS  Article  Google Scholar 

  7. Walter, M.J. et al. N. Engl. J. Med. 366, 1090–1098 (2012).

    CAS  Article  Google Scholar 

  8. Gerlinger, M. et al. N. Engl. J. Med. 366, 883–892 (2012).

    CAS  Article  Google Scholar 

  9. Magrangeas, F. et al. Leukemia 27, 473–481 (2013).

    CAS  Article  Google Scholar 

  10. Landau, D.A. et al. Cell 152, 714–726 (2013).

    CAS  Article  Google Scholar 

  11. Clappier, E. et al. J. Exp. Med. 208, 653–661 (2011).

    CAS  Article  Google Scholar 

  12. Notta, F. et al. Nature 469, 362–367 (2011).

    CAS  Article  Google Scholar 

  13. Papaemmanuil, E. et al. Blood 122, 3616–3627 (2013).

    CAS  Article  Google Scholar 

  14. Lohr, J.G. et al. Cancer Cell 25, 91–101 (2014).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Ross L Levine.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kleppe, M., Levine, R. Tumor Heterogeneity Confounds and Illuminates: Assessing the implications. Nat Med 20, 342–344 (2014).

Download citation

  • Published:

  • Issue Date:

  • DOI:

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing